Irlande - anglais - HPRA (Health Products Regulatory Authority)

vetoquinol uk limited - phenylpropanolamine hydrochloride - oral solution - 50 milligram(s)/millilitre - phenylpropanolamin - dogs - hormone

Irlande - anglais - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - phenylpropanolamine hydrochloride - syrup - 50 milligram(s)/millilitre - phenylpropanolamin

Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

gladron chemicals sdn bhd - phenylpropanolamine hydrochloride -

Malte - anglais - Malta Medicines Authority

wockhardt uk limited - amitriptyline hydrochloride - oral solution - amitriptyline hydrochloride 25 milligram(s)/5 millilitre - psychoanaleptics

États-Unis - anglais - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - terazosin hydrochloride anhydrous (unii: 8qop8z9955) (terazosin - unii:8l5014xet7) - terazosin 2 mg - terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules. the long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin capsules are also indicated for the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

États-Unis - anglais - NLM (National Library of Medicine)

mylan institutional inc. - terazosin hydrochloride anhydrous (unii: 8qop8z9955) (terazosin - unii:8l5014xet7) - terazosin 1 mg - terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules. the long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin capsules are also indicated for the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

États-Unis - anglais - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - terazosin hydrochloride anhydrous (unii: 8qop8z9955) (terazosin - unii:8l5014xet7) - terazosin 1 mg - terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules. the long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin capsules are also indicated for the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

États-Unis - anglais - NLM (National Library of Medicine)

physicians total care, inc. - terazosin hydrochloride (unii: d32s14f082) (terazosin - unii:8l5014xet7) - terazosin 1 mg - terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules. the long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin capsules are also indicated for the treatment of hypertension. terazosin capsules can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

États-Unis - anglais - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - terazosin hydrochloride (unii: d32s14f082) (terazosin - unii:8l5014xet7) - terazosin 1 mg - terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules. the long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin capsules are also indicated for the treatment of hypertension. terazosin capsules can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

États-Unis - anglais - NLM (National Library of Medicine)

akorn - promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494), phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - promethazine hydrochloride 6.25 mg in 5 ml - promethazine hydrochloride and phenylephrine hydrochloride syrup is indicated for the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. phenylephrine is contraindicated in patients with hypertension or with peripheral vascular insufficiency (ischemia may result with risk of gangrene or thrombosis of compromised vascular beds). phenylephrine should not be used in patients known to be hypersensitive to the drug or in those receiving a monoamine oxidase inhibitor (maoi).